Biomanufacturing is different from other processing industries. It is less able to sustain continuous end-to-end flows because it must contend with unique technical, practical, regulatory, and ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Higher antibody titers and a growing demand for smaller-volume, flexible processes are creating the need for more cost-effective downstream processing. Changes in the biopharmaceuticals market are ...